Equity Overview
Price & Market Data
Price: $6.18
Daily Change: +$0.01 / 0.16%
Range: $6.05 - $6.34
Market Cap: $741,488,000
Volume: 1,142,084
Performance Metrics
1 Week: -13.74%
1 Month: -1.62%
3 Months: -9.78%
6 Months: 127.2%
1 Year: 134.2%
YTD: 47.82%
Company Details
Employees: 26
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.